Shanafelt Armen
Insider CIK 1656151 · PTGX Director, 10% owner · ALRN Director · AGLE Director, 10% owner · SURF Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SURF Surface Oncology, Inc. | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2022-06-07 | 2022-06-09 | 43,000 | — | $0 | 43,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | P Buy | 2021-12-13 | 2021-12-13 | 14,685 | $3.65 | $53.6K | 150,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | P Buy | 2021-12-10 | 2021-12-13 | 13,516 | $3.65 | $49.3K | 135,315 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | P Buy | 2021-12-09 | 2021-12-13 | 121,799 | $3.67 | $447.0K | 121,799 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2021-06-08 | 2021-06-09 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SURF Surface Oncology, Inc. | A Award deriv | 2021-06-08 | 2021-06-10 | 17,700 | — | $0 | 17,700 | SEC↗ |
| SURF Surface Oncology, Inc. | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2020-06-08 | 2020-06-10 | 28,100 | — | $0 | 28,100 | SEC↗ |
| SURF Surface Oncology, Inc. | A Award deriv | 2019-10-01 | 2019-10-03 | 16,531 | — | $0 | 16,531 | SEC↗ |
| SURF Surface Oncology, Inc. | A Award deriv | 2019-07-01 | 2019-07-02 | 6,937 | — | $0 | 6,937 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2019-06-07 | 2019-06-07 | 12,400 | — | $0 | 12,400 | SEC↗ |
| SURF Surface Oncology, Inc. | A Award deriv | 2019-06-05 | 2019-06-06 | 12,100 | — | $0 | 12,100 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | A Award deriv | 2018-06-21 | 2018-06-25 | 10,000 | — | $0 | 10,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2018-06-07 | 2018-06-08 | 18,400 | — | $0 | 18,400 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2018-05-29 | 2018-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| SURF Surface Oncology, Inc. | C Conversion deriv | 2018-04-23 | 2018-04-23 | 7,000,000 | — | $0 | 0 | SEC↗ |
| SURF Surface Oncology, Inc. | C Conversion | 2018-04-23 | 2018-04-23 | 3,181,817 | — | $0 | 3,181,817 | SEC↗ |
| SURF Surface Oncology, Inc. | P Buy | 2018-04-23 | 2018-04-23 | 266,000 | $15.00 | $3.99M | 3,447,817 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2017-12-01 | 2017-12-05 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | A Award deriv | 2017-07-25 | 2017-07-27 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | C Conversion deriv | 2017-07-05 | 2017-07-07 | 1,907,373 | — | $0 | 0 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | C Conversion deriv | 2017-07-05 | 2017-07-07 | 1,654,411 | — | $0 | 0 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | C Conversion deriv | 2017-07-05 | 2017-07-07 | 1,443,972 | — | $0 | 0 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | C Conversion deriv | 2017-07-05 | 2017-07-07 | 3,390,885 | — | $0 | 0 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | P Buy | 2017-07-05 | 2017-07-07 | 250,000 | $15.00 | $3.75M | 1,094,987 | SEC↗ |
| ALRN AILERON THERAPEUTICS INC | C Conversion | 2017-07-05 | 2017-07-07 | 844,987 | — | $0 | 844,987 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2017-05-25 | 2017-05-26 | 12,000 | — | $0 | 12,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2016-09-13 | 2016-09-15 | 24,000 | — | $0 | 24,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion deriv | 2016-08-16 | 2016-08-16 | 9,841,333 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion deriv | 2016-08-16 | 2016-08-16 | 9,142,857 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion deriv | 2016-08-16 | 2016-08-16 | 3,000,000 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion | 2016-08-16 | 2016-08-16 | 630,541 | — | $0 | 837,437 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion | 2016-08-16 | 2016-08-16 | 678,712 | — | $0 | 1,516,149 | SEC↗ |
| PTGX Protagonist Therapeutics, | P Buy | 2016-08-16 | 2016-08-16 | 583,333 | $12.00 | $7.00M | 2,099,482 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion | 2016-08-16 | 2016-08-16 | 206,896 | — | $0 | 206,896 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2016-05-17 | 2016-05-19 | 24,000 | — | $0 | 24,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | C Conversion | 2016-04-12 | 2016-04-14 | 2,010,924 | — | $0 | 2,068,543 | SEC↗ |